StoxDr. Lal Path Labs vs Wockhardt: share price & financials comparison
NSE: LALPATHLAB vs WOCKPHARMA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Dr. Lal Path Labs vs Wockhardt at a glance
Dr. Lal Path Labs (LALPATHLAB) has a market capitalisation of ₹33,057 Cr, against ₹31,541 Cr for Wockhardt (WOCKPHARMA). Over the past year Wockhardt has returned +49.0%, compared with +27.5% for Dr. Lal Path Labs. On valuation, Dr. Lal Path Labs trades at a lower P/E of 56.7 versus 76.9. Dr. Lal Path Labs earns a higher return on equity (21.3% vs 7.9%). Dr. Lal Path Labs comes out ahead on size, profitability, growth and technicals. Across the scored metrics below, Dr. Lal Path Labs leads on 11 and Wockhardt on 5. On StoxGud's 10-point checklist, Dr. Lal Path Labs scores 9/10 and Wockhardt scores 7/10.
| Metric | Dr. Lal Path Labs | Wockhardt |
|---|---|---|
| Size | ||
| Market cap | ₹33,057 Cr | ₹31,541 Cr |
| Revenue (latest FY) | ₹2,763 Cr | ₹3,373 Cr |
| Net profit (latest FY) | ₹505 Cr | ₹213 Cr |
| Valuation | ||
| P/E | 56.7 | 76.9 |
| P/B | 12.04 | 6.12 |
| Dividend yield | 0.67% | — |
| Profitability | ||
| Return on equity | 21.3% | 7.9% |
| Net profit margin | 19.2% | 10.9% |
| Operating margin | 29.5% | 20.4% |
| Growth | ||
| Revenue growth (YoY) | +19.6% | +23.9% |
| Net profit growth (YoY) | +27.6% | +1.3% |
| Revenue CAGR (multi-year) | +11.8% | +4.5% |
| Financial health | ||
| Debt to equity | 0.00 | 0.42 |
| Momentum | ||
| 1-month return | +1.3% | -9.5% |
| 1-year return | +27.5% | +49.0% |
| 3-year CAGR | +14.2% | +102.7% |
| 5-year CAGR | +1.5% | +35.5% |
| 10-year CAGR | +12.9% | +10.0% |
| Distance from 52W high | -2.9% | -16.4% |
| Technicals | ||
| RSI (14) | 65 | 49 |
| Price vs 200-day avg | +19.3% | +13.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Dr. Lal Path Labs | Wockhardt |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 9/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Dr. Lal Path Labs or Wockhardt?
Dr. Lal Path Labs has a market cap of ₹33,057 Cr and Wockhardt has a market cap of ₹31,541 Cr as of 06 Nov 2026.
Which has a lower P/E, Dr. Lal Path Labs or Wockhardt?
Dr. Lal Path Labs has the lower P/E: Dr. Lal Path Labs trades at 56.7 and Wockhardt at 76.9.
Which gave better returns in the last year, Dr. Lal Path Labs or Wockhardt?
Wockhardt did better: Dr. Lal Path Labs returned +27.5% and Wockhardt returned +49.0% over one year.
Is Dr. Lal Path Labs or Wockhardt a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Dr. Lal Path Labs scores 9/10 and Wockhardt scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.